SCHEMBL10144978

SCHEMBL10144978

Nc1ccc(/C=C/c2cc(=O)c3cc(I)ccc3o2)cc1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.52
KDM4E B2RXH2 4/20 0.52
ALDH1A1 P00352 3/20 0.52
HPGD P15428 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
MAOA P21397 1/20 0.51
MAOB P27338 1/20 0.51
STS P08842 1/20 0.49
APP P05067 10/20 0.48
EGFR P00533 1/20 0.43
SRC P12931 1/20 0.43
LCK P06239 1/20 0.40
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4993834 1.00 MAPT (0.52) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL10144896 0.84 APP (0.65) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL4987282 0.84 APP (0.65) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL10144981 0.84 MAPT (0.52) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL4988880 0.84 MAPT (0.52) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL4989048 0.83 APP (0.62) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL10144983 0.83 APP (0.69) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL10144979 0.83 APP (0.62) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL4992744 0.81 MAOA (0.78) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL10144893 0.81 MAOA (0.78) MAPTKDM4EALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8192717-B2 Flavone derivative, chalcone derivative, styrylchromone derivative, or a coumarin derivative with high binding specificity to an amyloid beta protein, high permeability to a blood-brain barrier, and ability to rapidly disappear from sites other than cerebral senile plaque; also drug screening NAGASAKI UNIVERSITY (JP) 2012-06-05 US disclosed
US-20080131367-A1 Composition For Diagnosing Amyloid-Related Diseases Mori, Hiroshi (JP) 2008-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080131367-A1 Composition For Diagnosing Amyloid-Related Diseases APP, APBA1, FABP7 MAPT 20/4885KDM4E 3076/4885ALDH1A1 3190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.